Next Article in Journal
Molecular Basis of Bacterial Host Interactions by Gram-Positive Targeting Bacteriophages
Previous Article in Journal
Enzymes and Mechanisms Employed by Tailed Bacteriophages to Breach the Bacterial Cell Barriers
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(8), 398; https://doi.org/10.3390/v10080398

Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma

1
Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
2
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
3
Veterinary Diagnostic Laboratories, Colorado State University, Fort Collins, CO 80523, USA
*
Author to whom correspondence should be addressed.
Received: 16 July 2018 / Revised: 25 July 2018 / Accepted: 27 July 2018 / Published: 28 July 2018
(This article belongs to the Section Animal Viruses)
Full-Text   |   PDF [1734 KB, uploaded 28 July 2018]   |  

Abstract

Many oncolytic viruses that are efficacious in murine cancer models are ineffective in humans. The outcomes of oncolytic virus treatment in dogs with spontaneous tumors may better predict human cancer response and improve treatment options for dogs with cancer. The objectives of this study were to evaluate the safety of treatment with myxoma virus lacking the serp2 gene (MYXVΔserp2) and determine its immunogenicity in dogs. To achieve these objectives, dogs with spontaneous soft tissue sarcomas were treated with MYXVΔserp2 intratumorally (n = 5) or post-operatively (n = 5). In dogs treated intratumorally, clinical scores were recorded and tumor biopsies and swabs (from the mouth and virus injection site) were analyzed for viral DNA at multiple time-points. In all dogs, blood, urine, and feces were frequently collected to evaluate organ function, virus distribution, and immune response. No detrimental effects of MYXVΔserp2 treatment were observed in any canine cancer patients. No clinically significant changes in complete blood profiles, serum chemistry analyses, or urinalyses were measured. Viral DNA was isolated from one tumor swab, but viral dissemination was not observed. Anti-MYXV antibodies were occasionally detected. These findings provide needed safety information to advance clinical trials using MYXVΔserp2 to treat patients with cancer. View Full-Text
Keywords: oncolytic poxvirus; myxoma virus; sarcoma; canine oncolytic poxvirus; myxoma virus; sarcoma; canine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

MacNeill, A.L.; Weishaar, K.M.; Séguin, B.; Powers, B.E. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma. Viruses 2018, 10, 398.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top